5MC Stock Overview
A biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Leap Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.42 |
| 52 Week High | US$4.54 |
| 52 Week Low | US$1.48 |
| Beta | 0.22 |
| 11 Month Change | -19.33% |
| 3 Month Change | 0% |
| 1 Year Change | 15.24% |
| 33 Year Change | -89.12% |
| 5 Year Change | -58.63% |
| Change since IPO | -96.34% |
Recent News & Updates
Recent updates
Shareholder Returns
| 5MC | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -13.6% | -0.2% | 0.8% |
| 1Y | 15.2% | -16.9% | 9.1% |
Return vs Industry: 5MC exceeded the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: 5MC exceeded the German Market which returned 8.5% over the past year.
Price Volatility
| 5MC volatility | |
|---|---|
| 5MC Average Weekly Movement | 14.0% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 5MC's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 5MC's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 54 | Doug Onsi | www.leaptx.com |
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd.
Leap Therapeutics, Inc. Fundamentals Summary
| 5MC fundamental statistics | |
|---|---|
| Market cap | €93.10m |
| Earnings (TTM) | -€61.76m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.5x
P/E RatioIs 5MC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 5MC income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$64.82m |
| Earnings | -US$64.82m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.69 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 5MC perform over the long term?
See historical performance and comparison